Increased serum osteopontin is a risk factor for osteoporosis in menopausal women

Abstract

Serum OPN levels could be used as a biomarker for the early diagnosis of osteoporosis in postmenopausal women.

Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment

“…Our previous study indicated that plasma OPN levels could be used as a biomarker for the early diagnosis of osteoporosis in postmenopausal women [34]. In this study, we demonstrated that there is a sequential decrease in the plasma OPN level with the improvement in concomitant bone mineral density after intermittent PTH treatment in women with postmenopausal osteoporosis.…”

“…Our previous study indicated that plasma OPN levels could be used as a biomarker for the early diagnosis of osteoporosis in postmenopausal women [34].…”

Temporal Changes in Bone Composition, Architecture, and Strength Following Estrogen Deficiency in Osteoporosis

“…Osteopontin is a protein that preferentially accumulates at mineralised tissue interfaces [41] and plays an important role in regulating osteoclastogenesis and is thereby often used as an indicator of bone turnover [42]. One recent study has suggested that over-expression of osteopontin is a risk factor for osteoporosis [43] and bone loss is suppressed in OPN-deficient mice following ovariectomy, despite an increase in osteoclastogenesis [44]. In the current study, we show for the first time that estrogen deficiency induced an increase in osteopontin expression which remained elevated over time and that these changes occurred prior to significant changes in bone microarchitecture.…”

OPN Polymorphism is Associated with the Susceptibility to Cervical Spondylotic Myelopathy and its Outcome After Anterior Cervical Corpectomy and Fusion

“…It has been suggested that OPN may facilitate the adhesion (or detachment) of the osteoclast to the bone surface and act as a signaling molecule or a scaffold in normal bone metabolism and turnover [22,25,26]. In human, high OPN levels have been indicated as a risk factor for low bone mineral density in postmenopausal women and used as a biomarker for early osteoporosis diagnosis [27]. Studies have shown that a high level of osteopontin mRNA and protein expression occurs in both intramembranous and endochondral ossification, as well as remodeling bone, including the human osteophyte [28].…”